However, the LYPD1-directed bivalent low affinity TCB demonstrated compelling safety profiles in cynomolgus monkeys and showed selective targeting of LYPD1high and LYPD1medium-expressing tumor cells, supporting anti-LYPD1 TCBs for treatment of advanced stage HGSOC. The gene discussed is LYPD1; the disease is neoplasm.